Catheter Precision (VTAK)
XASE:VTAK
Want to see VTAK full AI Analyst Report?
VTAK Stock Chart & Stats
$1.81
-$0.02(-4.26%)
At close: 4:00 PM EST
$1.81
-$0.02(-4.26%)
Day’s Range― - ―
52-Week Range$0.75 - $15.68
Previous CloseN/A
Volume115.56K
Average Volume (3M)309.34K
Market Cap
$2.58M
Enterprise Value$12.50M
Total Cash (Recent Filing)$441.00K
Total Debt (Recent Filing)$11.99M
Price to Earnings (P/E)―
Beta1.35
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.79
Shares Outstanding2,692,473
10 Day Avg. Volume759,143
30 Day Avg. Volume309,336
Financial Highlights & Ratios
PEG Ratio-0.83
Price to Book (P/B)280.34
Price to Sales (P/S)2414.57
P/FCF Ratio-237.88
Enterprise Value/Market Cap4.84
Enterprise Value/Revenue11.29
Enterprise Value/Gross Profit24.42
Enterprise Value/Ebitda-0.85
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-60.8
Revenue Forecast (FY)$10.20M
Bulls Say, Bears Say
Bulls Say
Proprietary Electrophysiology Mapping CatheterOwning a proprietary EP mapping catheter provides a durable product differentiation in a high-barrier medical niche. Procedure-based device sales create recurring disposable demand per ablation, supporting a stable revenue stream if clinical adoption and reimbursement trends persist over months to years.
Rapid Revenue Growth From Small BaseVery strong revenue growth off a small base signals early commercial traction and potential product-market fit. If the company sustains this adoption curve, scaling revenue can leverage fixed costs, improve gross margins, and materially reduce financing pressure over a 2–6 month horizon and beyond.
Shareholder-approved Capital Structure FlexibilityBoard-authorized tools like a reverse split and approvals for preferred conversions give management durable flexibility to manage listing, raise structured capital, and simplify the cap table. This reduces procedural constraints on financing decisions and can preserve operational continuity during restructuring.
Bears Say
Sustained Negative Operating Cash FlowLarge, persistent cash burn creates an ongoing need for external financing and elevates dilution and refinancing risk. Over months this constrains the company's ability to invest in commercialization, hire sales talent, or execute R&D without additional capital, making strategic plans contingent on funding access.
Extreme Negative Profitability MarginsDeep, recurring operating and net losses indicate the cost structure far exceeds current revenue levels. Such extreme negative margins reflect poor capital efficiency and suggest substantial restructuring or sustained revenue acceleration is required to approach breakeven, raising solvency and execution risks over time.
Acquisition Pivot And Heavy Dilution RiskA strategic shift into aviation assets diverges from the core med‑device business and diverts management focus and capital. Funding the deal with convertible preferreds increases future dilution and complicates execution, adding structural integration and strategic coherence risks that persist beyond near-term quarters.
Catheter Precision News
VTAK FAQ
What was Catheter Precision’s price range in the past 12 months?
Catheter Precision lowest stock price was $0.75 and its highest was $15.68 in the past 12 months.
What is Catheter Precision’s market cap?
Catheter Precision’s market cap is $2.58M.
When is Catheter Precision’s upcoming earnings report date?
Catheter Precision’s upcoming earnings report date is Aug 17, 2026 which is in 74 days.
How were Catheter Precision’s earnings last quarter?
Currently, no data Available
Is Catheter Precision overvalued?
According to Wall Street analysts Catheter Precision’s price is currently Overvalued.
Does Catheter Precision pay dividends?
Catheter Precision does not currently pay dividends.
What is Catheter Precision’s EPS estimate?
Catheter Precision’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Catheter Precision have?
Catheter Precision has 2,692,473 shares outstanding.
What happened to Catheter Precision’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Catheter Precision?
Currently, no hedge funds are holding shares in VTAK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Catheter Precision
Catheter Precision, Inc. develops and delivers electrophysiology products to provide patients, hospitals, and physicians with technologies and solutions to improve the lives of patients with cardiac arrhythmias in the United States. The company's lead product is View into Ventricular Onset System, a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. It also provides LockeT, a suture retention device; and Amigo Remote Catheter System, a robotic arm that serves as a catheter control device. The company was formerly known as Ra Medical Systems, Inc and changed its name to Catheter Precision, Inc. in August 2023. Catheter Precision, Inc. is based in Fort Mill, South Carolina.
Technical Analysis
Ownership Overview
0.52%
Insiders
0.30% Mutual Funds
<0.01% Other Institutional Investors
99.17% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---